365 related articles for article (PubMed ID: 33031791)
1. Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.
Husain A; Byrareddy SN
Chem Biol Interact; 2020 Nov; 331():109282. PubMed ID: 33031791
[TBL] [Abstract][Full Text] [Related]
2. Repurposing old drugs as antiviral agents for coronaviruses.
Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
[TBL] [Abstract][Full Text] [Related]
3. Uncertainty about the Efficacy of Remdesivir on COVID-19.
Yoo JH
J Korean Med Sci; 2020 Jun; 35(23):e221. PubMed ID: 32537956
[No Abstract] [Full Text] [Related]
4. Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.
Bou Khalil R
Med Hypotheses; 2020 Sep; 142():109798. PubMed ID: 32413699
[No Abstract] [Full Text] [Related]
5. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.
Chakraborti S; Bheemireddy S; Srinivasan N
Mol Omics; 2020 Oct; 16(5):474-491. PubMed ID: 32696772
[TBL] [Abstract][Full Text] [Related]
6. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.
Clementi N; Ferrarese R; Criscuolo E; Diotti RA; Castelli M; Scagnolari C; Burioni R; Antonelli G; Clementi M; Mancini N
J Infect Dis; 2020 Aug; 222(5):722-725. PubMed ID: 32559285
[TBL] [Abstract][Full Text] [Related]
7. Drug Repurposing Study Pinpoints Potential COVID-19 Antivirals.
Abbasi J
JAMA; 2020 Sep; 324(10):928. PubMed ID: 32897326
[No Abstract] [Full Text] [Related]
8. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
9. Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19.
Saul S; Einav S
ACS Infect Dis; 2020 Sep; 6(9):2304-2318. PubMed ID: 32687696
[TBL] [Abstract][Full Text] [Related]
10. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment.
Maiese K
Curr Neurovasc Res; 2020; 17(3):332-337. PubMed ID: 32334502
[TBL] [Abstract][Full Text] [Related]
11. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 RNA polymerase as target for antiviral therapy.
Buonaguro L; Tagliamonte M; Tornesello ML; Buonaguro FM
J Transl Med; 2020 May; 18(1):185. PubMed ID: 32370758
[TBL] [Abstract][Full Text] [Related]
13. Drug Discovery Strategies for SARS-CoV-2.
Shyr ZA; Gorshkov K; Chen CZ; Zheng W
J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
[TBL] [Abstract][Full Text] [Related]
14. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.
Cao R; Hu H; Li Y; Wang X; Xu M; Liu J; Zhang H; Yan Y; Zhao L; Li W; Zhang T; Xiao D; Guo X; Li Y; Yang J; Hu Z; Wang M; Zhong W
ACS Infect Dis; 2020 Sep; 6(9):2524-2531. PubMed ID: 32786284
[TBL] [Abstract][Full Text] [Related]
15. α-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.
Williams SJ; Goddard-Borger ED
Biochem Soc Trans; 2020 Jun; 48(3):1287-1295. PubMed ID: 32510142
[TBL] [Abstract][Full Text] [Related]
16. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
Unni S; Aouti S; Thiyagarajan S; Padmanabhan B
J Biosci; 2020; 45(1):. PubMed ID: 33184246
[TBL] [Abstract][Full Text] [Related]
17. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication.
Touret F; Gilles M; Barral K; Nougairède A; van Helden J; Decroly E; de Lamballerie X; Coutard B
Sci Rep; 2020 Aug; 10(1):13093. PubMed ID: 32753646
[TBL] [Abstract][Full Text] [Related]
18. Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL
Chitranshi N; Gupta VK; Rajput R; Godinez A; Pushpitha K; Shen T; Mirzaei M; You Y; Basavarajappa D; Gupta V; Graham SL
J Transl Med; 2020 Jul; 18(1):278. PubMed ID: 32646487
[TBL] [Abstract][Full Text] [Related]
19. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
20. Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?
Alonso DF; Farina HG
Int J Antimicrob Agents; 2020 Sep; 56(3):106125. PubMed ID: 32739476
[No Abstract] [Full Text] [Related]
[Next] [New Search]
